½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå : Ä¡·áº°, ¾à¸®ÇÐÀû Ŭ·¡½ºº° : ¾à¸®ÇÐÀû Ŭ·¡½ºº°, À¯Åë ä³Îº°, Áö¿ªº°
Kidney Cancer Drugs Market, By Therapy: Targeted Therapy, Immunotherapy, and Chemotherapy, By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, and Others, By Distribution Channel, By Geography
»óǰÄÚµå : 1672798
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 73¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 110¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 6.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 73¾ï 1,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 6.10% 2032³â °¡Ä¡ ¿¹Ãø 110¾ï 7,000¸¸ ´Þ·¯
µµÇ¥. ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Kidney Cancer Drugs Market-IMG1

ÀǾàǰ ºÐ¼® ½ÃÇèÀº ½ÅÀå¾Ï(½Å¼¼Æ÷¾ÏÀ̶ó°íµµ ÇÔ)À» È®ÁøÇϱâ À§ÇÑ °úÇÐÀû ±â¼ú ¹× ¹æ¹ýÀÇ »ç¿ëÀ» ¸»ÇÕ´Ï´Ù. ½ÅÀå¾ÏÀº Àü ¼¼°è¿¡¼­ °¡Àå ÈçÇÑ ¾Ï Áß Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¸Å³â 40¸¸ ¸í ÀÌ»óÀÌ »õ·Ó°Ô Áø´ÜÀ» ¹Þ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ½ÅÀå¾Ï°ú °ü·ÃµÈ À§Çè ¿äÀÎÀ¸·Î´Â ´ã¹è »ç¿ë, ºñ¸¸, À¯ÀüÀû ¿äÀÎ, ƯÁ¤ µ¶¼Ò ³ëÃâ µîÀÌ ÀÖ½À´Ï´Ù. Ãʱ⠽ÅÀå¾ÏÀÇ °æ¿ì ÀÚ°¢Áõ»óÀÌ ¾ø´Â °æ¿ìµµ ÀÖÁö¸¸, ¼Òº¯¿¡ Çǰ¡ ¼¯¿© ³ª¿À°Å³ª ¿·±¸¸®°¡ ¾ÆÇÁ°Å³ª º¹ºÎ Á¾±«°¡ ¸¸Á®Áö´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. Ä¡·á ¿É¼ÇÀº ±¹¼Ò º´º¯¿¡ ´ëÇÑ ½ÅÀå ºÎºÐ ÀýÁ¦¼úÀ̳ª ±ÙÄ¡Àû ½ÅÀýÁ¦¼úºÎÅÍ ÁøÇ༺ »ç·Ê¿¡ ´ëÇÑ Ç¥Àû Ä¡·á¿Í ¸é¿ª ¿ä¹ý±îÁö ´Ù¾çÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¼¼°è ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀåÀº ¹ßº´·ü Áõ°¡, ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚ Á¢±Ù¼º Çâ»ó, °­·ÂÇÑ ½Å¾à ÆÄÀÌÇÁ¶óÀÎ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ÇâÈÄ ¼ö³â°£ Å« ÆøÀÇ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀåÀº Àü ¼¼°è ½Å¼¼Æ÷¾Ï À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °í·É Àα¸ Áõ°¡, ºñ¸¸À² Áõ°¡, Á÷Àå¿¡¼­ÀÇ µ¶¼Ò ³ëÃâ Áõ°¡¿Í °°Àº À§Çè ¿äÀÎ Áõ°¡°¡ Áúº´ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼±Áø±¹¿¡¼­ ÇÁ¸®¹Ì¾ö Ç¥ÀûÄ¡·áÁ¦ ¹× ¸é¿ªÄ¡·á¿¡ ´ëÇÑ È¯ÀÚ Á¢±Ù¼ºÀÌ °³¼±µÇ¸é¼­ ½ÃÀå ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ¼ö¼ú, ¹æ»ç¼± Ä¡·á, ¾à¼ö󸮸¦ º´ÇàÇÏ´Â Ä¡·á ±â°£ÀÌ ±æ¾îÁü¿¡ µû¶ó ȯÀÚµéÀº À¯Áö¿ä¹ý¿¡ ÀÇÁ¸ÇÏ´Â ±â°£ÀÌ ±æ¾îÁö°í ÀÖ½À´Ï´Ù. ½ÃÀå °³¹ß¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ°¡ ÀÖ´Â ¹Ý¸é, ÁÖ¿ä ÀǾàǰÀÇ Æ¯Çã ¸¸·á¿Í Á¦³×¸¯ ÀǾàǰ ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀÎÀÌ ÁÖ¿ä °³¹ß»çµéÀÇ ¼öÀÔ¿øÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï ±¹°¡ ½ÃÀåÀÇ ³ôÀº °¡°Ý Ã¥Á¤ ¹× Á¢±Ù¼º ¹®Á¦´Â ´õ ³ÐÀº ½ÃÀåÀ¸·ÎÀÇ Á¢±ÙÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ´Ù¾çÇÑ Áúº´ °æ·Î¸¦ Ÿ±êÀ¸·Î ÇÏ´Â ÀÓ»ó ÁßÀÎ ºÐÀÚ ÆÄÀÌÇÁ¶óÀÎÀÌ Ç³ºÎÇÏ¿© ÇâÈÄ ½ÃÀå È®´ë °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå, Ä¡·áº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå, ¾à¸®ÇÐÀû Ŭ·¡½ºº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ ½ÅÀå¾Ï Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Kidney Cancer Drugs Market is estimated to be valued at USD 7.31 Bn in 2025 and is expected to reach USD 11.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 7.31 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.10% 2032 Value Projection: USD 11.07 Bn
Figure. Kidney Cancer Drugs Market Share (%), By Region 2025
Kidney Cancer Drugs Market - IMG1

Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.

Market Dynamics:

The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.

Key Features of the Study:

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Kidney Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Kidney Cancer Drugs Market, By Therapy, 2020 - 2032, (USD Bn)

6. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2020 - 2032, (USD Bn)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

8. Global Kidney Cancer Drugs Market, By Region, 2020 - 2032, (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â